Evidence map›Paper›PMID 40269263›Full record

ArticleOncogene2025

USP14-IMP2-CXCL2 axis in tumor-associated macrophages facilitates resistance to anti-PD-1 therapy in gastric cancer by recruiting myeloid-derived suppressor cells.

Li You, Qian Wang, Tianxue Zhang, Hongwei Xiao, Mengjiao Lv, Hong Lv, Li Deng, Xuyao Zhang, Yu Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Ubiquitination and NOncology letters · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. RNA mCell biology and toxicology · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. CLEVER-1Frontiers in immunology · 2026
    Review
  16. Review
  17. Review
  18. Decoding RNF20: an epigenetic modifier and beyond.Frontiers in cell and developmental biology · 2026
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Li You *Department of Gastric Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.ORCID 0000-0003-2951-1616
Qian Wang *Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Tianxue Zhang *Yangpu Branch Campus, Shanghai Open University, Shanghai, 200082, China.ORCID 0009-0005-7701-4122
Hongwei Xiao *Key Laboratory of Animal Embryo Engineering and Molecular Breeding of Hubei Province, Institute of Animal Husbandry and Veterinary, Hubei Academy of Agricultural Science, Wuhan, 430064, China.
Mengjiao LvDepartment of Infectious Diseases, Shanghai East Hospital, Tongji University, Shanghai, 200120, China.
Hong LvDepartment of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.ORCID 0000-0002-2129-2781
Li DengDepartment of General Surgery, The Shanghai Public Health Clinical Center, Fudan University, Shanghai, 200032, China.ORCID 0000-0003-2845-7291
Xuyao ZhangDepartment of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, 201203, China. xuyaozhang@fudan.edu.cn.ORCID 0000-0003-1654-5550
Yu ZhangDepartment of Gastric Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. zyu722320@163.com.ORCID 0000-0002-3444-1985

Funding

National Natural Science Foundation of China (National Science Foundation of China) 32200745
6 · The paper itself

Abstract

Resistance to anti-PD-1 therapy remains a significant challenge in gastric cancer (GC) treatment. Here, we revealed that the USP14-IMP2-CXCL2 axis in tumor-associated macrophages (TAMs) drove resistance by recruiting myeloid-derived suppressor cells (MDSCs). Endoscopic biopsy samples were obtained from patients with inoperable GC who were candidates for anti-PD-1 therapy. Single-cell RNA sequencing (scRNA-seq) analysis showed a higher prevalence of USP14

Indexed as

Chemokine CXCL2Drug Resistance, NeoplasmMyeloid-Derived Suppressor CellsRNA-Binding ProteinsStomach NeoplasmsTumor-Associated MacrophagesUbiquitin ThiolesteraseAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansImmune Checkpoint InhibitorsMaleMiceProgrammed Cell Death 1 ReceptorChemokine CXCL2CXCL2 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorRNA-Binding ProteinsUbiquitin ThiolesteraseUSP14 protein, human

Identifiers

PMID40269263

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.